Table 2.
Tumor-associated antigens (TAAs) in mPC immunotherapeutics
| TAA | Function | Modalities for immunotherapy | Other expressing tissues | Unsuccessful therapies | Approved therapies | Ongoing trials |
|---|---|---|---|---|---|---|
| PSMA | Zinc metalloenzyme | Bi-specific antibodies, CAR-T, STEAP-1 | Salivary glands, kidney | N/A | N/A | PSMAxCD3 antibody CC-1 (NCT04104607), P-PSMA-101 CAR-T (NCT04249947), PSCA-CAR-T (NCT03873805), CART-PSMA-TGFβRDN (NCT04227275), BPX-601 CAR-T (NCT02744287), AMG 509 (NCT04221542), Pasotuxizumab (BAY 2010112) (NCT01723475), ES414 (NCT02262910), Adoptive transfer of autologous T cells (NCT01140373) |
| Folate uptake | ||||||
| PAP | Seminal fluid production | Vaccine + ICI | Not significant | N/A | Sipuleucel-T | NCT04090528, NCT02499835 |
| PSA | Serine protease | Vaccine + ICI | Not significant | Vaccine (NCT01322490) | N/A | NCT02933255, NCT02325557 |
| Forms semen coagulum | ||||||
| MUC1 | Cell adhesion, intracellular signaling | Vaccine, DC vaccine | Most epithelial cells. Many adenocarcinomas. Not expressed by normal prostate cells | N/A | N/A | NCT03481816 |
| PSCA | Unknown | Vaccine, mAb | Not significant | N/A | N/A | N/A |
| TARP | Androgen regulation. Mitochondrial lipid metabolism | DC vaccine | Breast adenocarcinoma | N/A | N/A | NCT02362451 |
PSMA prostate-specific membrane antigen, PAP prostate acid phosphatase, PSA prostate-specific antigen, MUC1 mucin-1, PSCA prostate stem cell antigen, STEAP-1 six transmembrane epithelial antigen of the prostate 1, TARP T cell receptor gamma chain alternate reading frame protein, CAR-T chimeric antigen receptor T cell, ICI immune checkpoint inhibitor therapy, DC dendritic cell, mAb monoclonal antibody